Brexit: UK Joining US-Led Project Orbis To Speed Cancer Drug Approvals

Joining the international regulatory collaboration could become a key route for the UK to remain an early and priority market for global launches after the end of the Brexit transition period, says the industry group, BIA.

Alarm clock — The UK is leaving the EU single market and customs union on 1 January 2021 • Source: Shutterstock

In January 2021 the UK will join Project Orbis, the US-led collaborative scheme that enables international regulators to simultaneously review and approve new cancer drugs faster.

The UK medicines agency, the MHRA, will join the scheme fully on 1 January, after the end of the Brexit...